GICS Sector : Healthcare
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases.The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.
Sight Sciences reported total revenue of $20.4 million for Q4 2025, representing a 7% increase year-over-year. Interventional Glaucoma revenue was $19.7 million, up 5% driven by increases in ordering accounts and average selling prices. Interventional Dry Eye revenue was $0.7 million, a significant increase from $0.3 million in the prior year. Gross margin remained strong at 87%, consistent with the prior year. The company's EPS loss was $0.07841, beating estimates of a loss of $0.15. For 2026, Sight Sciences initiated revenue guidance of $82 million to $88 million, representing growth of 6% to 14% compared to 2025.
Publication Date: Mar -06
The Interventional Glaucoma segment continues to be the main driver of revenue, with a focus on expanding the combo cataract segment and developing the underpenetrated stand-alone market. The company is making investments in its commercial infrastructure, including market access and commercial teams, to drive growth. As Paul Badawi mentioned, "We're in a much more stable market and reimbursement environment than we saw a year ago." The Interventional Dry Eye segment is showing promising traction, with revenue increasing to $0.7 million in Q4 2025.
Sight Sciences is well-positioned for growth in 2026, with a clear strategy to return to double-digit growth while maintaining operational rigor and financial discipline. Analysts estimate revenue growth of 15.4% for next year, which is slightly above the company's guidance. The company's focus on Interventional Glaucoma and Interventional Dry Eye is expected to drive growth.
Using the current stock price and the reported EPS, the P/E Ratio is -5.47, indicating that the stock is trading at a premium. The P/S Ratio is 2.71, which is relatively high compared to the industry average. The EV/EBITDA ratio is -4.68, suggesting that the company's enterprise value is not justified by its EBITDA. The company's ROE and ROIC are both negative, indicating that the company is not generating profits.
Sight Sciences is cautiously optimistic about its growth prospects, with a focus on executing its commercial strategy and driving adoption of its Interventional Glaucoma and Interventional Dry Eye technologies. The company's guidance for 2026 suggests that it is confident in its ability to drive growth while maintaining financial discipline. As the company continues to execute on its strategy, investors will be watching to see if it can achieve its growth objectives. The upcoming launch of Ultra, the next iteration of OMNI, is expected to drive growth in the Interventional Glaucoma segment.
Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Mar -06
Sight Sciences, Inc. (SGHT) Q4 2025 Earnings Call Transcript
Mar -05
Sight Sciences (SGHT) Reports Q4 Earnings: What Key Metrics Have to Say
Mar -05
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Beats Revenue Estimates
Mar -04
Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance
Mar -04
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Feb -25
Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Feb -18
Americana Partners LLC Grows Stock Holdings in Sight Sciences, Inc. $SGHT
Jan -21
Surgical Glaucoma from Sight Sciences, Inc. growth driven by increasing prevalence of glaucoma, aging population, and rising demand for minimally invasive procedures. Advancements in micro-invasive glaucoma surgery (MIGS) technology, expanding reimbursement coverage, and growing adoption in emerging markets also contribute to the 10.0% growth rate.
Sight Sciences, Inc.'s Dry Eye segment growth is driven by increasing prevalence of dry eye disease, growing demand for minimally invasive treatments, and expanding adoption of OMNI Surgical System. Additionally, rising awareness of dry eye as a chronic condition, increasing healthcare expenditure, and strategic partnerships are contributing to the 10.0% growth rate.
A microcatheter-based surgical system designed for canaloplasty and viscodilation of Schlemm's canal in the eye.
A 360-degree trabeculotomy system for the treatment of open-angle glaucoma.
A surgical system for the treatment of glaucoma, featuring a proprietary, patented micro-invasive glaucoma surgery (MIGS) device.
The threat of substitutes for Sight Sciences, Inc. is moderate due to the availability of alternative technologies and products in the market.
The bargaining power of customers is high due to the presence of large and established customers who can negotiate prices and terms.
The bargaining power of suppliers is low due to the presence of multiple suppliers and the company's ability to negotiate prices.
The threat of new entrants is moderate due to the presence of barriers to entry, such as high capital requirements and regulatory hurdles.
The intensity of rivalry is high due to the presence of established competitors and the need to differentiate products and services.
| Value | |
|---|---|
| Debt Weight | 22.30% |
| Debt Cost | 15.24% |
| Equity Weight | 77.70% |
| Equity Cost | 17.49% |
| WACC | 16.99% |
| Leverage | 28.70% |
Value: 6.4
Growth: 5.8
Quality: 3.6
Yield: 0.0
Momentum: 9.5
Volatility: 1.0
1-Year Total Return ->
Value: 6.6
Growth: 1.7
Quality: 4.7
Yield: 0.0
Momentum: 8.5
Volatility: 4.3
1-Year Total Return ->
Value: 4.4
Growth: 5.4
Quality: 2.9
Yield: 0.0
Momentum: 10.0
Volatility: 2.7
1-Year Total Return ->
Value: 6.6
Growth: 5.7
Quality: 3.8
Yield: 0.0
Momentum: 5.0
Volatility: 1.0
1-Year Total Return ->
Value: 9.6
Growth: 1.4
Quality: 4.2
Yield: 0.0
Momentum: 3.0
Volatility: 3.3
1-Year Total Return ->
Value: 10.0
Growth: 1.6
Quality: 5.0
Yield: 0.0
Momentum: 0.0
Volatility: 0.0
1-Year Total Return ->